BioCentury
ARTICLE | Company News

Amgen, Array BioPharma deal

August 12, 2013 7:00 AM UTC

Amgen is terminating a 2009 deal under which it had worldwide rights to develop and commercialize Array's small molecule glucokinase activator (GKA) program. All rights to the GKA program will revert...